- Home
- TVTX
as 08-01-2025 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Upcoming Earnings Alert:
Get ready for potential market movements as Travere Therapeutics Inc. TVTX prepares to release earnings report on 06 Aug 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $33.33 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.93 - $25.29 | Next Earning Date: | 08-06-2025 |
| Revenue: | $273,533,000 | Revenue Growth: | 75.65% |
| Revenue Growth (this year): | 71.61% | Revenue Growth (next year): | 43.45% |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness
Insider Monkey
2 months ago
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Business Wire
2 months ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
Business Wire
2 months ago
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
Business Wire
2 months ago
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
PR Newswire
2 months ago
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
Business Wire
3 months ago
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.